A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.
A Randomized,Double Blind,Placebo Parallel Controlled,Multicenter Clinical Sthdy of Ginkgo Diterpene Lactone Meglumine Injection for Acute Ischemic Stroke Efficacy Safety.
Sponsor: Beijing Bionovo Medicine Development Co., Ltd.
This PHASE2 trial investigates Ischemic Stroke and is currently completed. Beijing Bionovo Medicine Development Co., Ltd. leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jan 2021 — Apr 2023 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Enrolling By Invitation → Unknown Status
-
Jan 2017 — Mar 2018 [monthly]
Enrolling By Invitation PHASE2
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Bionovo Medicine Development Co., Ltd.
- Beijing Tiantan Hospital
For direct contact, visit the study record on ClinicalTrials.gov .